Crystal Structures Reveal an Induced-fit Binding of a Substrate-like Aza-peptide Epoxide to SARS Coronavirus Main Peptidase

Journal of Molecular Biology

Volumn 366, Issue 3, 2007, Pages 916-932

  Lee, Ting Wai ^a   Cherney, Maia M ^a   Liu, Jie ^b   James, Karen Ellis ^c   Powers, James C ^c   Eltis, Lindsay D ^b   James, Michael N G ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

aza peptide epoxide; induced fit binding; SARS coronavirus main peptidase; structure based drug design; X ray crystallography

Indexed keywords

EPOXIDE; HETEROCYCLIC COMPOUND; PEPTIDASE;

ARTICLE; CONFORMATIONAL TRANSITION; CRYOPROTECTION; CRYSTAL STRUCTURE; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SARS CORONAVIRUS; VIROGENESIS; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

SARS CORONAVIRUS;

EID: 33846637686     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2006.11.078     Document Type: Article

References (54)

1. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1953-1966
2. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1967-1976
3. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 (2003) 1319-1325
4. Groneberg D.A., Hilgenfeld R., and Zabel P. Molecular mechanisms of severe acute respiratory syndrome (SARS). Respir. Res. 6 (2005) 8
5. Bartlam M., Yang H., and Rao Z. Structural insights into SARS coronavirus proteins. Curr. Opin. Struct. Biol. 15 (2005) 664-672
6. Thiel V., Herold J., Schelle B., and Siddell S.G. Viral replicase gene products suffice for coronavirus discontinuous transcription. J. Virol. 75 (2001) 6676-6681
7. Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S., et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 84 (2003) 2305-2315
8. Ziebuhr J., Snijder E.J., and Gorbalenya A.E. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol. 81 (2000) 853-879
9. Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J. Biol. Chem. 279 (2004) 1637-1642
10. Shi J., Wei Z., and Song J. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors. J. Biol. Chem. 279 (2004) 24765-24773
11. Kuo C.J., Chi Y.H., Hsu J.T., and Liang P.H. Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. Biochem. Biophys. Res. Commun. 318 (2004) 862-867
12. Chou C.Y., Chang H.C., Hsu W.C., Lin T.Z., Lin C.H., and Chang G.G. Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry 43 (2004) 14958-14970
13. Chen S., Chen L., Tan J., Chen J., Du L., Sun T., et al. Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization: biochemical and thermodynamic investigation in conjunction with molecular dynamic simulations. J. Biol. Chem. 280 (2005) 164-173
14. Hsu W.C., Chang H.C., Chou C.Y., Tsai P.J., Lin P.I., and Chang G.G. Critical assessment of important regions in the subunit association and catalytic action of the severe acute respiratory syndrome coronavirus main protease. J. Biol. Chem. 280 (2005) 22741-22748
15. Ziebuhr J., Heusipp G., and Siddell S.G. Biosynthesis, purification, and characterization of the human coronavirus 229E 3C-like proteinase. J. Virol. 71 (1997) 3992-3997
16. Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., and Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300 (2003) 1763-1767
17. Anand K., Palm G.J., Mesters J.R., Siddell S.G., Ziebuhr J., and Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 21 (2002) 3213-3224
18. Huang C., Wei P., Fan K., Liu Y., and Lai L. 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry 43 (2004) 4568-4574
19. Schechter I., and Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27 (1967) 157-162
20. Bacha U., Barrila J., Velazquez-Campoy A., Leavitt S.A., and Freire E. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 43 (2004) 4906-4912
21. Jain R.P., Pettersson H.I., Zhang J., Aull K.D., Fortin P.D., Huitema C., et al. Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J. Med. Chem. 47 (2004) 6113-6116
22. Wu C.Y., Jan J.T., Ma S.H., Kuo C.J., Juan H.F., Cheng Y.S., et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl Acad. Sci. USA 101 (2004) 10012-10017
23. Kao R.Y., Tsui W.H., Lee T.S., Tanner J.A., Watt R.M., Huang J.D., et al. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem. Biol. 11 (2004) 1293-1299
24. Blanchard J.E., Elowe N.H., Huitema C., Fortin P.D., Cechetto J.D., Eltis L.D., and Brown E.D. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem. Biol. 11 (2004) 1445-1453
25. Yang H., Yang M., Ding Y., Liu Y., Lou Z., Zhou Z., et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl Acad. Sci. USA 100 (2003) 13190-13195
26. Ghosh A.K., Xi K., Ratia K., Santarsiero B.D., Fu W., Harcourt B.H., et al. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J. Med. Chem. 48 (2005) 6767-6771
27. Yang H., Xie W., Xue X., Yang K., Ma J., Liang W., et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 3 (2005) e324
28. Chen L., Gui C., Luo X., Yang Q., Gunther S., Scandella E., et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J. Virol. 79 (2005) 7095-7103
29. Lee T.W., Cherney M.M., Huitema C., Liu J., James K.E., Powers J.C., et al. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. J. Mol. Biol. 353 (2005) 1137-1151
30. Asgian J.L., James K.E., Li Z.Z., Carter W., Barrett A.J., Mikolajczyk J., et al. Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases. J. Med. Chem. 45 (2002) 4958-4960
31. Barrett A.J., and Rawlings N.D. Evolutionary lines of cysteine peptidases. Biol. Chem. 382 (2001) 727-733
32. James K.E., Gotz M.G., Caffrey C.R., Hansell E., Carter W., Barrett A.J., et al. Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases). Biol. Chem. 384 (2003) 1613-1618
33. James K.E., Asgian J.L., Li Z.Z., Ekici O.D., Rubin J.R., Mikolajczyk J., et al. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8. J. Med. Chem. 47 (2004) 1553-1574
34. Powers J.C., Asgian J.L., Ekici O.D., and James K.E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102 (2002) 4639-4750
35. Hegyi A., Friebe A., Gorbalenya A.E., and Ziebuhr J. Mutational analysis of the active centre of coronavirus 3C-like proteases. J. Gen. Virol. 83 (2002) 581-593
36. Tan J., Verschueren K.H., Anand K., Shen J., Yang M., Xu Y., et al. pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J. Mol. Biol. 354 (2005) 25-40
37. Xu T., Ooi A., Lee H.C., Wilmouth R., Liu D.X., and Lescar J. Structure of the SARS coronavirus main proteinase as an active C2 crystallographic dimer. Acta Crystallog. sect. F 61 (2005) 964-966
38. Hunter C.A., Lawson K.R., Perkins J., and Urch C.J. Aromatic interactions. J. Chem. Soc., Perkin Trans. 2 (2001) 651-669
39. Burley S.K., and Petsko G.A. Dimerization energetics of benzene and aromatic amino acid side-chains. J. Am. Chem. Soc. 108 (1986) 7995-8001
40. Serrano L., Bycroft M., and Fersht A.R. Aromatic-aromatic interactions and protein stability. Investigation by double-mutant cycles. J. Mol. Biol. 218 (1991) 465-475
41. Burley S.K., and Petsko G.A. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science 229 (1985) 23-28
42. Hsu M.F., Kuo C.J., Chang K.T., Chang H.C., Chou C.C., Ko T.P., et al. Mechanism of the maturation process of SARS-CoV 3CL protease. J. Biol. Chem. 280 (2005) 31257-31266
43. Shi J., and Song J. The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain. FEBS J. 273 (2006) 1035-1045
44. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
45. Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallog. sect. D 50 (1994) 760-763
46. Potterton E., Briggs P., Turkenburg M., and Dodson E. A graphical user interface to the CCP4 program suite. Acta Crystallog. sect. D 59 (2003) 1131-1137
47. Vagin A., and Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallog. 30 (1997) 1022-1025
48. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog. sect. D 53 (1997) 240-255
49. McRee D.E. XtalView/Xfit-a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125 (1999) 156-165
50. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26 (1993) 283-291
51. Satow Y., Cohen G.H., Padlan E.A., and Davies D.R. Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. J. Mol. Biol. 190 (1986) 593-604
52. Cohen G.H. ALIGN: a program to superimpose protein coordinates, accounting for insertions and deletions. J. Appl. Cryst. 30 (1997) 1160-1161
53. Wallace A.C., Laskowski R.A., and Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8 (1995) 127-134
54. Brünger A.T. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 355 (1992) 472-475